Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2

Wang, Jun1; Shao, Liang2; Liang, Jing3,4; Wu, Qingming5; Zhu, Baoli6; Deng, Qiwen7; Liu, Zelin8; Liu, Liqiong8; Wang, Danyu8; Yu, Zhijian7; Tan, Xiaohua9; Wang, Fuxiang10; Meng, Jingye9; Xu, Xiaojun11; Xia, Zhongjun12; Li, Zhiming13; Wang, Hua12; Wang, Liang14; Wu, Wei15; Xie, Qi3,4; Huang, Xiaoxing16; Sun, Zhiqiang17; Zhang, Yu18; Zhou, Hao19; Zhou, Hui20; Yang, Wenyan21; Ren, Hua22; Liu, Zhe23; Qiao, Mingqiang24; Tang, Feifei25; Qi, Xiaofei26; Wu, Huijing27; Deng, Lijuan28; Gao, Li29; Zhang, Hongyan30; Chen, Peng31; Zhang, Hongyu32; Zhang, Xinyou33; Zhou, Jihao33; Tu, Chuanqing34; Guan, Ling35; Yin, Qian36; Shu, Rong37; Chen, Feng38; He, Mingxin5; Wang, Qiang39; Guo, Zhi8

2023-12-01

10.4103/jcrt.JCRT_782_23

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS   影响因子和分区

0973-1482

1998-4138

In December 2022, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became dominant in China due to its high infectivity and lower mortality rate. The risk of critical illness and mortality among patients with hematologic malignancies who contracted SARS-CoV-2 was particularly high. The aim of this study was to draft a consensus to facilitate effective treatments for these patients based on the type and severity of the disease. Following the outbreak of the novel coronavirus in China, a steering committee consisting of experienced hematologists was formed by the Specialized Committee of Oncology and Microecology of the Chinese Anti-Cancer Association. The expert group drafted a consensus on the management and intervention measures for different types of hematologic malignancies based on the clinical characteristics of the Omicron variant of the SARS-CoV-2 infection, along with relevant guidelines and literature. The expert group drafted independent recommendations on several important aspects based on the epidemiology of the Omicron variant in China and the unique vulnerability of patients with hematologic malignancies. These included prophylactic vaccinations for those with hematologic malignancies, the use of plasma from blood donors who recovered from the novel coronavirus infection, the establishment of negative pressure wards, the use of steady-state mobilization of peripheral blood hematopoietic stem cells, the provision of psychological support for patients and medical staff, and a focus on maintaining a healthy intestinal microecology.

Chemotherapy hematological malignancies hematopoietic stem cell transplantation immunotherapy omicron SARS-CoV-2

SCI

英语

其他

Oncology

Oncology

WOS:001138228600005

WOLTERS KLUWER MEDKNOW PUBLICATIONS

Web of Science

1.Hongkong Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
2.Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan, Peoples R China
3.Shandong First Med Univ, Affiliated Hosp 1, Dept Oncol, Jinan, Peoples R China
4.Shandong Prov Qianfoshan Hosp, Shandong Key Lab Rheumat Dis & Translat Med, Shandong Lung Canc Inst, Jinan, Peoples R China
5.Wuhan Univ Sci & Technol, Med Coll, Hubei Prov Key Lab Occupat Hazard Identificat & C, Inst Infect Immunol & Tumor Microenvironm, Wuhan, Peoples R China
6.Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China
7.Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Infect Dis, Shenzhen, Peoples R China
8.Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
9.Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Peoples Hosp Shenzhen 3, Dept Hematol & Oncol,Affiliated Hosp 2, Shenzhen, Peoples R China
10.Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Dept Infect Dis, Affiliated Hosp 2,Peoples Hosp Shenzhen 3, Shenzhen, Peoples R China
11.Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China
12.Sun Yat Sen Univ, Canc Ctr, Dept Hematol, State Key Lab Oncol South China, Guangzhou, Peoples R China
13.Sun Yat Sen Univ, Canc Ctr, Med Dept, State Key Lab Oncol South China, Guangzhou, Peoples R China
14.Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing, Peoples R China
15.Guangdong Prov Ctr Dis Control & Prevent, Guangdong Prov Inst Publ Hlth, Guangzhou, Peoples R China
16.Wuhan Univ, Dept Blood Transfus, Zhongnan Hosp, Wuhan, Peoples R China
17.Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
18.Southern Med Univ, Nanfang Hosp, Dept Hematol, Shenzhen, Peoples R China
19.Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China
20.Cent South Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Dept Lymphoma & Hematol,Hunan Canc Hosp, Changsha, Hunan, Peoples R China
21.Shangdong First Med Univ & Shangdong Acad Med Sci, Jinan, Peoples R China
22.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
23.Tianjin Univ, Med Coll, Tianjin, Peoples R China
24.Shanxi Univ, Sch Life Sci, Taiyuan, Peoples R China
25.Peking Univ, Peking Univ Inst Hematol, Peoples Hosp, Beijing, Peoples R China
26.Soochow Univ, Dept Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
27.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Lymphoma Med,Breast Canc & Soft Tissue Tumor, 116 South Zhuodaoquan Rd, Wuhan, Peoples R China
28.Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
29.Army Med Univ, Xinqiao Hosp, Med Ctr Hematol, Chongqing, Peoples R China
30.Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Med Ctr 5, Beijing, Peoples R China
31.Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Med Ctr 5, Beijing, Peoples R China
32.Peking Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
33.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Dept Hematol,Clin Med Coll 2,Affiliated Hosp 1, Shenzhen, Peoples R China
34.Shenzhen Univ, Dept Hematol, Affiliated Hosp 2, Shenzhen Baoan Hosp, Shenzhen, Peoples R China
35.Southern Med Univ, Dongguan Peoples Hosp, Affiliated Dongguan Hosp, Dongguan, Peoples R China
36.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thyroid & Breast Surg, Wuhan, Peoples R China
37.Third Peoples Hosp Hubei Prov, Wuhan, Peoples R China
38.Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Wuhan, Peoples R China
39.Wuhan Univ Sci & Technol, Wuhan Asia Gen Hosp, Med Coll, Wuhan, Peoples R China

Wang, Jun,Shao, Liang,Liang, Jing,et al. Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2[J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS,2023,19(6).

Wang, Jun.,Shao, Liang.,Liang, Jing.,Wu, Qingming.,Zhu, Baoli.,...&Guo, Zhi.(2023).Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2.JOURNAL OF CANCER RESEARCH AND THERAPEUTICS,19(6).

Wang, Jun,et al."Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2".JOURNAL OF CANCER RESEARCH AND THERAPEUTICS 19.6(2023).